BackAyala Pharmaceuticals Overview

Ayala Pharmaceuticals Current Assets

Track Ayala Pharmaceuticals's current assets ($3.2M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$3.19M
↓ 91.98% YoYΔ $-36.55M vs prior year quarter

Peer trimmed avg / median

Loading

Ayala Pharmaceuticals Current Assets History

Loading

Ayala Pharmaceuticals vs. peers: Current Assets Comparison

Loading

Ayala Pharmaceuticals Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ayala Pharmaceuticals (AYLA) FAQ

Ayala Pharmaceuticals (AYLA) currently reports a current assets of $3.2M as of December 2022. That compares with $40M in the prior-year period — down 92.0% year over year. Use the charts on this page to explore Ayala Pharmaceuticals's current assets history and peer comparisons.

Ayala Pharmaceuticals's current assets decreased from $40M to $3.2M — a 92.0% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ayala Pharmaceuticals reported $3.2M in current assets as of December 2022. That compares with $40M in the prior-year period — down 92.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current assets of $3.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ayala Pharmaceuticals, and consider following AYLA for alerts when major investors trade the stock.

Ayala Pharmaceuticals is classified in the Healthcare sector. On current assets, it currently shows $3.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AYLA with unrelated industries.